Duopa (carbidopa and levodopa enteral suspension – AbbVie) — Cigna

Initial criteria

• Patient is diagnosed with advanced Parkinson’s disease; AND
• Patient is experiencing 'off' episodes (examples include muscle stiffness, slow movements, or difficulty starting movements); AND
• Patient has tried an oral extended-release carbidopa/levodopa therapy and meets ONE of the following (i or ii): i) Patient had significant intolerance, according to the prescriber; OR ii) Patient had inadequate efficacy, according to the prescriber; AND
• Patient has previously tried THREE other treatments for 'off' episodes (examples include entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys [opicapone capsules], or Xadago [safinamide tablets]); AND
• Medication is prescribed by or in consultation with a neurologist

Approval duration

1 year